Analytical Data
-
基因名
Prostatic acid phosphatase/ACPP
- Application
-
别名
Cytosolic-activating factor
-
种属
Escherichia coli
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P0A6A8
-
表达区间
1-78aa
-
分子量
24.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Prostatic acid phosphatase (PAP), also known as ACPP (acid phosphatase, prostate), is an enzyme predominantly expressed in the prostate gland, playing a significant role in various physiological processes including the regulation of prostate function and metabolism of phosphate esters. Its elevation is clinically significant, particularly in the context of prostate cancer, where it serves as a biomarker for disease progression and prognosis. Research has increasingly focused on the recombinant production of PAP, which offers several advantages such as the availability of large quantities for characterization and therapeutic application. The recombinant forms of PAP are investigated for their potential in targeted cancer therapies and vaccine development due to their immunogenic properties. Additionally, the enzymatic activity and structural features of recombinant ACPP are studied to understand its biological function and to explore its utility in clinical diagnostics. Overall, the research surrounding recombinant PAP/ACPP is pivotal for advancing prostate cancer diagnostics and therapies, providing insights into the molecular mechanisms underlying prostate health and disease.
